|
IPC classes for russian patent Chemical compounds, pharmaceutical cmposition, containing them, their application (versions) and method of binding erα and erβ -estrogen receptors (RU 2352555):
Another patents in same IPC classes:
 Long-chain alkylphosphonic acids as soft steel corrosion inhibitors and their production / 2337914
Invention relates to phosphoroorganic chemistry, namely, to method of obtaining long-chain alkylphosphonic acids, possessing anticorrosion activity, based on α-olefins of industrial fraction C16-C18 and C20-C26. Invention can be applied for protection of pipelines, reservoirs, construction metallic structures, equipment for extraction, transportation and processing oil and gas, in metal processing. Long-chain alkylphosphonic acids are obtained by interaction of α-olefins of industrial fraction C16-C18 and C20-C26 with O,O-dimethylphosphorous acid in molar ratio 1:(1.0-2.0) in presence of benzoyl peroxide in amount of 1.0-5.0% of weight of dimethylphosphorous acid at 110-150°C during 10-12 hours in absence of solvent with further hydrolysis of intermediate higher O,O-dimethyl(alkyl) phosphonates with hydrochloric acid with heating, obtaining target product which represents mixture of long-chain alkylphosphonic acids.
 Acidic phosphorous containing complex forming reagent and method of obtaining it (versions) / 2331651
The invention pertains to an acidic phosphorous containing reagent, is used in the oil industry, heat energy, textile industry, production of mineral fertilizers and household chemistry, and to methods of obtaining the reagent. The reagent (conventional name "АФК-1") contains the following in given mass %: acetoxyethylidenediphosphonic acid 50.0-95.0 mass %, acetic acid - 29.5-0.5 mass %, the rest is acetic anhydride to 100. The quantitative composition of the indicated reagent is determined by the method of obtaining it and the ratios of the initial reagents. The method of obtaining the reagent involves adding acetic anhydride to a suspension of acetic and phosphorous acid at temperature of 60-90°C for a period of 1.5 hours. The reaction mixture is kept at 100-110°C for 1 hour and acidic impurities are distilled off to a controlled volume of distillate. Similar methods are developed based on phosphorous containing wastes from production of acid chlorides of higher fatty acids. The wastes are treated with water or a water solution of acetic acid with subsequent separation of the organic layer of fatty acids, after which the residue, containing phosphorous acid, is treated with phosphorous tri-chloride and acetic anhydride at 115-130°C, and acidic impurities are distilled off to the controlled distillate volume.
 Acidic phosphorous containing complex-forming reagent and method of obtaining it / 2331650
Invention pertains to the chemistry of phosphorous organic compounds, and specifically to an acidic phosphorous containing complex-forming reagent, which can be used in the oil industry, heat energy, textile industry, production of mineral fertilizers and household chemistry, and to the method of obtaining it. The acidic phosphorous containing complex-forming reagent (conventional name "АФК-2") contains the following in mass %: acetoxyethylidenediphosphonic acid - 50-95 mass %, acetic acid - 50-5 mass %. The method of obtaining the composition involves adding phosphorous tri-chloride, acetic acid and water simultaneously to glacial acetic acid in molar ratios equal to 1:(4.5-5.5):(1.93-1.95), at temperature of 35-45°C with subsequent keeping of the reaction mixture at 110-120°C for a period of 2 hours and controlled distillation of acidic impurities to the required distillate volume.
Method of obtaining inhibitor of precipitation of mineral salts / 2329270
Invention pertains to the method of obtaining an inhibitor of precipitation of mineral salts, The inhibitor is obtained by reaction of hexamethylenediamine and ammonium chloride with formaldehyde and phosphorous acid in a medium of diluted hydrochloric acid at high temperature with subsequent neutralisation of the obtained solution using sodium hydroxide to pH of 6.5±1.0. The process is carried out with molar ratio of hexamethylenediamine to ammonium chloride of 1:3-6.
 Plasma carboxypeptidase b inhibitors / 2323223
Invention describes compound of the formula (I): ![]() wherein R 1 means hydrogen atom (H); R 2 means -SH, -S-C(O)-R 8, -P(O)(OR 5) 2, -P(O)(OR 5)R 6, -P(O)(OR 5)-R 7-C(O)-R 8, -P(O)(OR 5)-R 7-N(R 5)-S(O) 2-R 9 or -P(O)(OR 5)-R 7-N(R 5)-C(S)-N(R 6) 2; R 3 means tetrazole, -C(O)OR 6, -C(O)O-R 7-OC(O)R 5; R 4 means optionally substituted aryl, or R 4 means N-heterocyclyl. Also, invention describes compounds of the formula (II): ![]() and (III): ![]() wherein X means -CH 2- or -O-, and pharmaceutical compositions comprising indicated compounds. Proposed compounds possess inhibitory effect on activity of plasma carboxypeptidase B and used as anti-thrombosis agents.
 Method for preparing monohydroperfluoroalkanes, bis-(perfluoroalkyl)phosphinates and perfluoroalkylphosphonates / 2319705
Invention describes a method for synthesis of monohydroperfluoroalkanes, bis-(perfluoroalkyl)phosphinates and perfluoroalkylphosphonates. Method involves treatment of at least one perfluoroalkylphosphorane with at least one base wherein base(s) are chosen from group consisting of alkali-earth metal hydroxides, metalloorganic compound in useful solvent or at least one organic base and an acid in useful reaction medium. Also, invention describes novel perfluoroalkylphosphonates and bis-(perfluoroalkyl)phosphinates, using novel perfluoroalkylphosphonates and bis-(perfluoroalyl)phosphinates as ionic liquids, catalysts of phase transfer or surfactants.
 Method for preparing copper (ii), zinc (ii), nickel (ii) and cobalt (ii) nitrilotri-(methylenephosphonates)(2-) / 2314313
Invention relates to a method for preparing copper (II), zinc (II), nickel (II) and cobalt (II) nitrilotri-(methylenephosphonates)(2-) that involves crystallization from aqueous solutions prepared by interaction of metal (II) compound with nitrilotri-(methylenephosphonic) acid or its salt with sodium potassium or ammonium in aqueous medium at temperature from -5°C to 105°C under atmosphere pressure. As a reactive of the metal (II) compound source the waste from manufacturing printing plates and galvanic covers can be used. The end products can be used in preparing the complex electrolytes and solutions for applying metallic covers by electrochemical and chemical methods in aims for inhibition against the equipment corrosion, and for preparing other compounds of metals with nitrilotri-(methylenephosphonic) acid.
 Phosphonic acid compounds as serine proteinase inhibitors / 2311421
Invention relates to phosphonic acid compounds used as inhibitors of serine proteinase of the general formula (I): ![]() wherein R 1 is chosen from group comprising piperidinyl, pyrrolidinyl and 1,3,8-triazaspiro[4,5]dec-8-yl (wherein heterocyclic ring as added to nitrogen atom in ring) and -N(R 7R 80 wherein this heterocyclic ring is substituted optionally with one or two substitutes chosen independently from group comprising the following compounds: (a) C 1-C 8)-alkyl substituted optionally at terminal carbon atom with a substitute chosen from group comprising aryl, heteroaryl; c) phenyl and naphthalenyl; i) benzothiazolyl; R 7 is chosen from group comprising hydrogen atom and (C 1-C 8)-alkyl; R 8 is chosen from group comprising: (aa) (C 1-C 8)-alkyl; (ab) cycloalkyl; (ac) cycloalkenyl, and (ad) heterocyclyl (wherein R 8 is added to carbon atom in ring) wherein (ab) cycloalkyl; (ac) cycloalkenyl, and (ad) heterocyclyl (wherein heterocyclyl (ad) comprises at least one cyclic nitrogen atom) substitutes and cycloalkyl moiety (aa) of a substitute is substituted optionally with substitutes chosen independently from group comprising: (ba) (C 1-C 8)-alkyl substituted at terminal carbon atom with a substitute chosen from group comprising amino-group (with two substitutes chosen independently from group comprising hydrogen atom and (C 1-C 8)-alkyl); (bb) (C 1-C 8)-alkoxy-group substituted at terminal carbon atom with a substitute chosen from group comprising carboxyl; (bc) carbonyl substituted with a substitute chosen from group comprising (C 1-C 8)-alkyl, aryl, aryl-(C 2-C 8)-alkenyl; (bd) aryl; (be) heteroaryl; (bf) amino-group substituted with two substitutes chosen independently from group comprising hydrogen atom and (C 1-C 8)-alkyl; (bh) halogen atom; (bi) hydroxy-group; (bk) heterocyclyl wherein (bd) is aryl substitute, and heteroaryl moiety (bc) comprise a substitute (halogen atom) 1-3; R 4 is chosen from group comprising aryl and heteroaryl wherein heteroaryl comprises halogen atom as a substitute; R 2 and R 3 are bound with benzene ring and represent hydrogen atom, and R 2 and R 3 form in common optionally at least one ring condensed with benzene ring forming polycyclic system wherein this polycyclic system is chosen from group comprising (C 9-C 14)-benzocondensed cycloalkenyl, (C 9-C 14)-benzocondensed phenyl; R 5 is chosen from group comprising hydrogen atom and (C 1-C 8)-alkyl; R 6 is chosen from group comprising (C 1-C 8)-alkyl and hydroxy-group; Y is absent, and X represents a single substitute that is added by a double bond and represents oxygen atom (O), and Z is chosen from group comprising a bond, hydrogen atom, and its salts. Also, invention relates to a method for synthesis of these compounds, to their composition inhibiting serine proteinase and to a method for its preparing. Proposed invention describes a method for treatment of inflammatory or serine proteinase-mediated disorder.
 Acidified indanylamines and their use as pharmaceutical preparations / 2339614
In acidified indanylamines of general formula (I) ![]() R 1-R 4 have values given in description, A represents CH 2, CHOH, B represents CH 2 and R 5 represents aryl or heteroaryl group, possibly substituted with substituents, listed in description. Said compounds are useful in regulation of endothelial nitrogen oxide synthase (eNOS) and, therefore they can be useful for production of medications for treatment of stable and unstable angina pectoris, Prinzmetal's angina, acute coronary syndrome, impaired heart function, cardiac infarction, stroke, thrombosis, peripheral artery occlusive disease, endothelial dysfunction, atherosclerosis, hypertension, lung hypertension, symptomatic hypertension, renovascular hypertension, erectile dysfunction, diabetes or diabetes complications, nephropathy, retinopathy, limited memory function, limited learning ability.
![Method for preparing derivatives of thieno[3,2-c]pyridine and used intermediate compounds](http://img.russianpatents.com/img_data/148/1485238-s.gif) Method for preparing derivatives of thieno[3,2-c]pyridine and used intermediate compounds / 2322446
Invention relates to a new method for synthesis of derivative of thieno[3,2-c]pyridine of the formula (1): ![]() (ticlopidine and clopidogrel). Method involves interaction of compound of the formula (2e): ![]() with compound of the formula (3): ![]() or its salt wherein R represents hydrogen atom or methoxycarbonyl; each among X' and Y' represents independently chlorine, bromine atom, methanesulfonyl or p-toluenesulfonyl, and to novel intermediate compounds and methods for their synthesis. Ticlopidine and clopidogrel possess the high inhibitory activity with respect to blood platelets aggregation and antithrombosis activity.
 Ester compounds and their using in medicine / 2293721
Invention relates to novel ester compounds represented by the formula (1): ![]() wherein values for R 1, R 2, A, X, R 3, R 4, Alk 1, Alk 2, l, m, D, R 8 and R 9 are determined in the invention claim. Also, invention relates to inhibitor of matrix metalloproteinase (MTP), a pharmaceutical composition able to inhibit activity of MTP selectively, agents used in treatment or prophylaxis of hyperlipidemia, arteriosclerosis, coronary artery diseases, obesity, diabetes mellitus or hypertension wherein the pharmaceutical composition is prepared in capsulated formulation, and to a biphenyl compound of the formula (100) given in the invention description.
 Biphenylsulfonylcyanamides, method for their preparing and their applying as drugs / 2247111
Invention relates to new biphenylsulfonylcyanamides of the formula (I): ![]() wherein R1 means: 1. (C 1-C 8)-alkyl; 4. -C nH 2n-nn-Y wherein nn = 0 or 2 and n = 0-4, and n is not 0 or 1 if nn = 2; 5. C nH 2n-nn-Y wherein nn = 0 or 2 and n = 1-4, and n is not 1 if nn = 2, and 1 hydrogen atom in bivalent residue C nH 2n-nn is substituted with amino-group or NR(22)R(23); R2 means: 2. (C 1-C)-alkyl; 4. (C 2-C 12)-alkenyl; 5. (C 2-C 8)-alkynyl; 6. -C nH 2n-nn-Z wherein nn = 0 or 2; n = 0-4, and n is not or 1 if nn = 2; 7. -C nH 2n-nn-Z wherein nn = 0 or 2; n = 1-4, and n is not 1 if nn = 2, and 1 hydrogen atom in bivalent residue C nH 2n-nn is substituted with a residue taken among a series: 1. phenyl; 3. NR(22)R(23); 5. COOR(16); R3 and R4 mean hydrogen atom; R5, R6 and R7 mean independently of one another hydrogen atom (H), (C 1-C 8)-alkyl; SO 2-(C 1-C 4)-alkyl, F, Cl, Br, J, OR(10) wherein R(10) means hydrogen atom, (C 1-C 4)-alkyl that is substituted if necessary with methoxy- or ethoxy-group; R(9) means OR(13) wherein R(13) means hydrogen atom, H,(C 1-C 8)-alkyl; X means carbonyl group, -CO-CO- or sulfonyl group; Y and Z mean independently of one another: 1. phenyl, 1-naphthyl, 2-naphthyl; 2. one of residues determined in cl. 1 substituted with 1-5 similar or different residues taken among a series: phenyl, F, Cl, Br, J, CF 3, SO qR(18), OR(16), NR(19)R(20), -CN, NO 2, COR(9), or two residues form methylenedioxy-group; 3. furyl, thienyl, pyridyl, benzimidazolyl, indolyl, benzothiophenyl, dihydroquinazolinyl; 5. (C 3-C 10)-cycloalkyl wherein cyclopropyl, cyclopentyl, cyclohexyl and indalyl are preferable; 6. one of residues determined in cl. 5 substituted with phenyl; R(16) means: 1. hydrogen atom; 2. (C 1-C 4)-alkyl; 3. (C 1-C 4)-alkyl substituted with (C 1-C 4)-alkoxy-group; R(19) and R(20) mean independently: hydrogen atom (H), (C 1-C 4)-alkyl; R(22) and R(23) mean independently of one another hydrogen atom (H) or CO-OR(24) wherein R924) means -C nH 2n-phenyl wherein n = 1-4; q = 2; and their physiologically acceptable salts. Compound of the formula (I) inhibit sodium-dependent chloride-bicarbonate exchange "NCBE".
 N-sulfonylpiperidinylmethylene derivatives with antibacterial activity / 2221778
The invention relates to new N-sulfonylpiperidinylmethylene derivative of the formula I
 < / BR>
where n = 1; R 1means 1-C 6alkyl, C 3-C 6cycloalkyl, 2-C 6alkenyl, C 1-C 6haloalkyl or a group NR 11R 12where R 11and R 12each independently from one another mean H, C 1-C 6alkyl; R 2means N; R 3means 1-C 6alkyl; R 4, R 5, R 6and R 7have the same or different values and each independently from one another mean H, C 1-C 4alkyl; R 8means C 1-C 6alkyl; a represents C 1-C 6alkylen; means phenyl, optionally substituted by 1-3 substituents, which may be the same or different and selected from the group comprising C 1-C 8alkyl, C 1-C 8haloalkyl, 1-C 8alkoxy, C 1-C 8haloalkoxy, C 2-C 8alkanoyl, halogen, C 1-C 8alkoxycarbonyl, nitro; or naphthyl or thienyl
 Substituted guanidine thiophenemethylamine acid and drug / 2193033
The invention relates to substituted guanidines thiophenemethylamine acid of the formula I
 < / BR>
where mean:
at least one of the substituents R(1), R(2) and R(3)
- O p-(CH 2) s-C qF 2q+1, R(40)CO - or R(31)SO k-;
p is zero or 1;
s is zero, 1, 2, 3 or 4;
q 1,2, 3,4, 5, 6, 7 or 8;
k is zero, 1 or 2;
R(40) alkyl with 1, 2, 3, 4, 5, 6, 7 or 8 C-atoms, perfluoroalkyl with 1, 2, 3, 4, 5, 6, 7 or 8 C-atoms,
cycloalkyl with 3, 4, 5, 6, 7 or 8 C-atoms or phenyl which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF, methyl or methoxy;
R(31) alkyl with 1, 2, 3, 4, 5, 6, 7 or 8 C-atoms, perfluoroalkyl with 1, 2, 3, 4, 5, 6, 7 or 8 C-atoms, cycloalkyl with 3, 4, 5, 6, 7 or 8 C-atoms, or phenyl which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3, methyl or methoxy;
or
R(31) NR(41)R(42);
R(41)and R(42)
independently from each other hydrogen, alkyl with 1, 2, 3 or 4 C-atoms,
perfluoroalkyl with 1, 2, 3 or 4 C-atoms,
or
R(41)and R(42)
together 4 or 5 methylene groups, of which CH 2-group may be replaced by oxygen, S, NH, N-CH 3or N-benzyl;
and sootwetstwii-O gaWITH raH 2raR(10);
PA zero or 1;
mA zero, 1, 2, 3, 4, 5, 6, 7 or 8;
ga zero or 1;
ha zero, 1, 2, 3 or 4;
R(10) cycloalkyl with 3, 4, 5, 6, 7 or 8 C-atoms or phenyl, where the phenyl is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3, methyl and methoxy;
R(4) and R(5)
independently from each other hydrogen, F, Cl, Br, I, CN, alkyl with 1, 2, 3, 4, 5, 6,
7 or 8 C-atoms, perfluoroalkyl with 1, 2, 3, 4, 5, 6, 7 or 8 C-atoms, cycloalkyl with 3, 4, 5, 6, 7 or 8 C-atoms or phenyl which is not substituted or is substituted by 1-3 substituents selected from the group consisting of F, Cl, CF 3, methyl, methoxy and NR(14)R(15);
R(14)R(15)
independently from each other H, alkyl with 1, 2, 3 or 4 C-atoms or perfluoroalkyl of 1, 2, 3 or 4 C-atoms
and their pharmaceutically tolerable salts
 Derivatives tamilcanadian, the retrieval method and intermediate products / 2191181
The invention relates to new derivatives of tamilcanadian with the General formula (I) wherein R' represents 2-thienyl or 3-thienyl radical, R represents ceanorhaditis or a radical of the formula-C(O) - and R2 is optional saturated or unsaturated cyclic hydrocarbon radical or aryl radical
The method of obtaining 2-fullcarbon acid / 2240999
The invention relates to improvements in the method of producing 2-fullcarbon acid, used in the manufacture of chemicals, pharmaceuticals, agricultural chemicals, resins and other products
|
FIELD: chemistry.
SUBSTANCE: invention relates to novel compounds of formula (I), including its pharmaceutically acceptable salts, solvates, ethers and amides, possessing ability to bind ERα- and ERβ-estrogen receptors, to pharmaceutical composition based on them, to versions of applying claimed compounds in medication preparation and to method of binding ERα- and ERβ-estrogen receptors. ![]() (I), where R1 represents H, OH or C1-12alkoxy, or halogen; R2 represents H, OH or halogen; R3 represents C1-12alkyl, halogeno-C1-12alkyl, C3-10cycloalkyl, C1-12alkoxy or C1-12alkoxyC1-12alkyl; R4 represents H or C1-12alkoxy; R5 represents H, halogen or halogeno-C1-12alkyl; R6 represents -(Y)z-R7; R8 represents phenyl or 5- or 6-member heteroaryl, containing N, O or S as heteroatom, where said phenyl and heteroaryl are possibly substituted with OH, halogeno, halogenoC1-12alkyl or C1-12alkoxy. Values R7, Y and z are presented in invention formula.
EFFECT: novel compounds possess useful biological properties.
19 cl, 7 dwg, 1 tbl, 70 ex
The text descriptions are given in facsimile form.                                                                                           ![]()                                               ![]()                                         
1. The compound of formula (I):
 ,
including its pharmaceutically acceptable salt, solvate, ester and amides,
DG is R 1represents H, HE or1-12alkoxy, or halogen;
R2represents H, Oh or halogen;
R3represents a C1-12alkyl, halogeno-C1-12alkyl, C3-10cycloalkyl,1-12alkoxy or1-12alkoxyl1-12alkyl;
R4represents N or C1-12aloxi;
R5represents H, halogen or halogeno-C1-12alkyl;
R6represents a -(Y)z-R7;
z is 0 or 1;
Y represents-CRe=CRf-;
when z is 0, then R7represents cyano, -CO2Ra, -(CH2)tCO2Ra, -O(CH2)tCO2Ra, -(CH2)tOH, -O(CH2)tOH, -O(CH2)tO(CH2)tOH, -CONRaRb, -NRaSO2Rdor-NRaC(O)Rc;
when z is 1, then R7represents-CO2Ra, -(CH2)tCO2Ra, -(CH2)tOH,
-CONRaRbor-PO3HRa;
t is from 1 to 8;
R8represents phenyl or 5 - or 6-membered heteroaryl containing N, O or S as a heteroatom, where mentioned phenyl and heteroaryl may HE substituted, halogen, halogeno1-12the alkyl or C1-12alkoxy;
Rarepresents N or C1-12alkyl;
Rbrepresents N or C 1-12alkyl;
Rcrepresents a C1-12alkyl, possibly substituted-CO2H or-CO2CH3;
Rdrepresents a C1-12alkyl, halogeno-C1-12alkyl or phenyl, possibly substituted C1-12by alkyl;
or Raand Rbcan be combined with the atoms to which they are linked, with the formation of 5 - or 6-membered heterocyclyl group containing an N atom as the heteroatom, possibly substituted-CO2N or1-12by alkyl; and
each of Reand Rfindependently from each other selected from H, C1-12of alkyl, halogen, halogeno-C1-12the alkyl.
2. The compound according to claim 1, including its pharmaceutically acceptable salt, solvate, ester and amides,
where z is 0, then R7represents cyano, -CO2H, -(CH2)tCO2H, -O(CH2)tCO2H, -(CH2)tOH, -O(CH2)tOH, -O(CH2)tO(CH2)tOH, -CONRaRb, -NRaSO2Rdor-NRaC(O)Rc;
when z is 1, then R7represents-CO2H, -(CH2)tCO2H, -(CH2)tOH, -CONRaRbor-PO3HRa;
Rarepresents a C1-12alkyl;
Rbrepresents a C1-12alkyl;
Rcrepresents a C1-12alkyl; and
Rdis the battle With 1-12alkyl or phenyl, possibly substituted C1-12the alkyl.
3. The compound according to claim 1, where the specified alkyl represents a C1-9alkyl, and alkoxy represents a C1-8alkoxy.
4. The compound according to claim 1, where R1represents H or HE.
5. The compound according to claim 4, where R1is a HE.
6. The compound according to claim 1, where R4represents N.
7. The compound according to claim 1, where R5represents a halogen or halogeno-C1-12alkyl.
8. The connection according to claim 7, where R5represents halogeno-C1-12alkyl.
9. The compound according to claim 1, where R6represents-CH=CH-CO2N.
10. The compound according to claim 1, where z is 0, and R7represents-CO2N.
11. The compound according to claim 1, where R8represents phenyl, 3-forfinal or 4-forfinal.
12. A compound selected from:
1-({4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}carbonyl)-4-piperidinecarboxylic acid;
1-({4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}carbonyl)-4-piperidinecarboxylic acid;
4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]benzoic acid;
(2E)-3-[4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-(trifluoromethyl)phenyl]-2-propanolol acid;
(2E)-3-{3-fluoro-4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
1,1,1-Cryptor-N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naftol the Nile)oxy]phenyl}methanesulfonamide;
(2E)-3-[4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-3-(trifluoromethyl)phenyl]-2-propanolol acid;
N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-4-methylbenzenesulfonamide;
3-({4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}amino)-3-oxopropanoic acid;
(2E)-3-(4-{[6-hydroxy-2-(4-hydroxyphenyl)-3-methyl-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-{4-[(3-ethyl-6-hydroxy-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
7-ethyl-5-({4-[(1E)-3-(4-methyl-1-piperazinil)-3-oxo-1-propen-1-yl]phenyl}oxy)-6-phenyl-2-naphthalenol;
(2E)-3-(4-{[6-hydroxy-3-(1-methylethyl)-2-phenyl-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-{4-[(3-butyl-6-hydroxy-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-{4-[(3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-{4-[(6-hydroxy-2-phenyl-3-propyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-(4-{[6-hydroxy-3-(2-methylpropyl)-2-phenyl-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-{4-[(6-hydroxy-3-pentyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-(4-{[6-hydroxy-2-phenyl-3-(3,3,3-cryptochromes)-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-{4-[(7-fluoro-6-hydroxy-2-phenyl-3-propyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-[4-({3-[(metiloksi)methyl]-2-phenyl-1-naphthalenyl}oxy)phenyl]-2-propanolol acid;
(2E)-3-{4-[(3-cyclopropyl-6-hydroxy-2-phenyl-1-NAF is linil)oxy]phenyl}-2-propanolol acid;
(2E)-3-(4-{[3-butyl-2-(4-forfinal)-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-(4-{[3-butyl-2-(4-hydroxyphenyl)-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-{4-[(7-fluoro-6-hydroxy-2-phenyl-3-propyl-1-naphthalenyl)oxy]phenyl}-2-propenamide;
(2E)-3-{4-[(3-butyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-(4-{[2-phenyl-3-(trifluoromethyl)-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
4-{[2-(4-hydroxyphenyl)-3-(trifluoromethyl)-1-naphthalenyl]oxy}benzoic acid;
(2E)-3-{4-[(6-hydroxy-3-octyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
{2-[4-(6-hydroxy-3-methyl-2-phenylnaphthalene-1 yloxy)phenyl]vinyl}phosphonic acid;
3-[4-(6-hydroxy-3-methyl-2-thiophene-3-ineptly-1 yloxy)phenyl]acrylic acid;
3-{4-[2-(4-forfinal)-6-hydroxy-3-methylnaphthalene-1-yloxy]phenyl}acrylic acid;
3-{4-[6-hydroxy-3-methyl-2-(3-triptoreline)naphthalene-1-yloxy]phenyl}acrylic acid;
3-[4-(2-furan-2-yl-6-methoxy-3-methylnaphthalene-1-yloxy)phenyl]acrylic acid;
3-[4-(6-methoxy-3-methyl-2-pyridine-4-ineptly-1 yloxy)phenyl]acrylic acid;
3-[4-(6-hydroxy-3-methyl-2-phenylnaphthalene-1 yloxy)phenyl]-2-methylacrylate acid;
2-[4-(6-hydroxy-3-methyl-2-phenylnaphthalene-1 yloxy)benzylidene]-3-methylmalonic acid;
3-{4-[2-(4-forfinal)-6-hydroxy-3-propylation-1 yloxy]-2-triptoreline}-2-methylacrylate acid;
3-{4-[2-(4-forfinal)-6-hydroxy-propylation-1 yloxy]-2-triptoreline}-2-methylacrylamide;
2-chloro-3-[4-(6-hydroxy-3-methyl-2-phenylnaphthalene-1 yloxy)phenyl]acrylic acid;
({4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}oxy)acetic acid;
4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]benzonitrile;
(2E)-3-[4-[(3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-(trifluoromethyl)phenyl]-2-propanolol acid;
7-methyl-5-({4-[(1E)-3-oxo-3-(1-piperidinyl)-1-propen-1-yl]phenyl}oxy)-6-phenyl-2-naphthalenol;
(2E)-3-(4-{[6-hydroxy-2-(3-hydroxyphenyl)-3-methyl-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
3-(4-{[6-hydroxy-2-(3-hydroxyphenyl)-3-methyl-1-naphthalenyl]oxy}phenyl)propanoic acid;
3-(4-{[6-hydroxy-2-(4-hydroxyphenyl)-3-methyl-4-(metiloksi)-1-naphthalenyl]oxy}phenyl)propanoic acid;
(2E)-3-(4-{[7-hydroxy-2-(4-hydroxyphenyl)-3-methyl-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
3-(4-{[7-hydroxy-2-(4-hydroxyphenyl)-3-methyl-1-naphthalenyl]oxy}phenyl)propanoic acid;
N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}methanesulfonamide;
N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}acanalonia;
2,2,2-Cryptor-N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}acanalonia;
N-[4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-(trifluoromethyl)phenyl]methanesulfonamide;
N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-were}methanesulfonamide;
4-{[2-(4-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)be what sainoi acid;
(2E)-3-[4-{[2-(3-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)phenyl]-2-propanolol acid;
4-{[2-(4-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}benzoic acid;
(2E)-3-[4-{[2-(4-forfinal)-6-hydroxy-3-propyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)phenyl]-2-propanolol acid;
(2E)-3-[4-{[2-(4-forfinal)-6-hydroxy-3-propyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)phenyl]-2-propenamide;
4-{[2-(4-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)benzamide;
methyl-4-{[2-(3-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)benzoate;
4-[(4-{[3-methyl-6-(metiloksi)-2-phenyl-1-naphthalenyl]oxy}phenyl)oxy]butane acid;
2-({2-[(4-{[3-methyl-6-(metiloksi)-2-phenyl-1-naphthalenyl]oxy}phenyl)oxy]ethyl}oxy)ethanol;
5-{[4-({2-[(2-hydroxyethyl)oxy]ethyl}oxy)phenyl]oxy}-7-methyl-6-phenyl-2-naphthalenol;
6-(3-forfinal)-5-{[4-({2-[(2-hydroxyethyl)oxy]ethyl}oxy)-3-(trifluoromethyl)phenyl]oxy}-7-methyl-2-naphthalenol;
{[4-{[2-(3-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)phenyl]oxy}acetic acid; and
6-(3-forfinal)-5-{[4-[(2-hydroxyethyl)oxy]-3-(trifluoromethyl)phenyl]oxy}-7-methyl-2-naphthalenol,
including its pharmaceutically acceptable salt, solvate, ester and amides.
13. (2E)-3-[4-{[2-(3-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)phenyl]-2-Papanova acid, its pharmaceutically acceptable salt, solvate or with whom you esters or amides.
14. The compound according to claim 1, selected from
1-({4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}carbonyl)-4-piperidinecarboxylic acid;
4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]benzoic acid;
(2E)-3-[4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-(trifluoromethyl)phenyl]-2-propanolol acid;
(2E)-3-{3-fluoro-4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
1,1,1-Cryptor-N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}methanesulfonamide;
(2E)-3-[4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-3-(trifluoromethyl)phenyl]-2-propanolol acid;
N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-4-methylbenzenesulfonamide;
3-({4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}amino)-3-oxopropanoic acid;
(2E)-3-(4-{[6-hydroxy-2-(4-hydroxyphenyl)-3-methyl-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-{4-[(3-ethyl-6-hydroxy-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
7-ethyl-5-({4-[(1E)-3-(4-methyl-1-piperazinil)-3-oxo-1-propen-1-yl]phenyl}oxy)-6-phenyl-2-naphthalenol;
(2E)-3-(4-{[6-hydroxy-3-(1-methylethyl)-2-phenyl-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-{4-[(3-butyl-6-hydroxy-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-{4-[(3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-{4-[(6-hydroxy-2-phenyl-3-propyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-(4{[6-hydroxy-3-(2-methylpropyl)-2-phenyl-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-{4-[(6-hydroxy-3-pentyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-(4-{[6-hydroxy-2-phenyl-3-(3,3,3-cryptochromes)-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-{4-[(7-fluoro-6-hydroxy-2-phenyl-3-propyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-[4-({3-[(metiloksi)methyl]-2-phenyl-1-naphthalenyl}oxy)phenyl]-2-propanolol acid;
(2E)-3-{4-[(3-cyclopropyl-6-hydroxy-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-(4-{[3-butyl-2-(4-forfinal)-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-(4-{[3-butyl-2-(4-hydroxyphenyl)-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
(2E)-3-{4-[(7-fluoro-6-hydroxy-2-phenyl-3-propyl-1-naphthalenyl)oxy]phenyl}-2-propenamide;
(2E)-3-{4-[(3-butyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
(2E)-3-(4-{[2-phenyl-3-(trifluoromethyl)-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
4-{[2-(4-hydroxyphenyl)-3-(trifluoromethyl)-1-naphthalenyl]oxy}benzoic acid;
(2E)-3-{4-[(6-hydroxy-3-octyl-2-phenyl-1-naphthalenyl)oxy]phenyl}-2-propanolol acid;
{2-[4-(6-hydroxy-3-methyl-2-phenylnaphthalene-1 yloxy)phenyl]vinyl}phosphonic acid;
3-[4-(6-hydroxy-3-methyl-2-thiophene-3-ineptly-1 yloxy)phenyl]acrylic acid;
3-{4-[2-(4-forfinal)-6-hydroxy-3-methylnaphthalene-1-yloxy]phenyl}acrylic acid;
3-{4-[6-hydroxy-3-methyl-2-(3-triptoreline)naphthalene-1-yloxy]phenyl}acrylic acid;
3-[4-(2-furan-2-yl-6-labels and-3-methylnaphthalene-1-yloxy)phenyl]acrylic acid;
3-[4-(6-methoxy-3-methyl-2-pyridine-4-ineptly-1 yloxy)phenyl]acrylic acid;
3-[4-(6-hydroxy-3-methyl-2-phenylnaphthalene-1 yloxy)phenyl]-2-methylacrylate acid;
2-[4-(6-hydroxy-3-methyl-2-phenylnaphthalene-1 yloxy)benzylidene]-3-methylmalonic acid;
3-{4-[2-(4-forfinal)-6-hydroxy-3-propylation-1 yloxy]-2-triptoreline}-2-methylacrylate acid;
3-{4-[2-(4-forfinal)-6-hydroxy-3-propylation-1 yloxy]-2-triptoreline}-2-methylacrylamide;
2-chloro-3-[4-(6-hydroxy-3-methyl-2-phenylnaphthalene-1 yloxy)phenyl]acrylic acid;
({4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}oxy)acetic acid;
4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]benzonitrile;
(2E)-3-[4-[(3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-(trifluoromethyl)phenyl]-2-propanolol acid;
7-methyl-5-({4-[(1E)-3-oxo-3-(1-piperidinyl)-1-propen-1-yl]phenyl}oxy)-6-phenyl-2-naphthalenol;
(2E)-3-(4-{[6-hydroxy-2-(3-hydroxyphenyl)-3-methyl-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
3-(4-{[6-hydroxy-2-(3-hydroxyphenyl)-3-methyl-1-naphthalenyl]oxy}phenyl)propanoic acid;
3-(4-{[6-hydroxy-2-(4-hydroxyphenyl)-3-methyl-4-(metiloksi)-1-naphthalenyl]oxy}phenyl)propanoic acid;
(2E)-3-(4-{[7-hydroxy-2-(4-hydroxyphenyl)-3-methyl-1-naphthalenyl]oxy}phenyl)-2-propanolol acid;
3-(4-{[7-hydroxy-2-(4-hydroxyphenyl)-3-methyl-1-naphthalenyl]oxy}phenyl)propanoic acid;
N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthas is linil)oxy]phenyl}methanesulfonamide;
N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}acanalonia;
2,2,2-Cryptor-N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]phenyl}acanalonia;
N-[4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-(trifluoromethyl)phenyl]methanesulfonamide;
N-{4-[(6-hydroxy-3-methyl-2-phenyl-1-naphthalenyl)oxy]-2-were}methanesulfonamide;
4-{[2-(4-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)benzoic acid;
(2E)-3-[4-{[2-(3-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)phenyl]-2-propanolol acid;
4-{[2-(4-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}benzoic acid;
(2E)-3-[4-{[2-(4-forfinal)-6-hydroxy-3-propyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)phenyl]-2-propanolol acid;
(2E)-3-[4-{[2-(4-forfinal)-6-hydroxy-3-propyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)phenyl]-2-propenamide;
4-{[2-(4-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)benzamide;
methyl-4-{[2-(3-forfinal)-6-hydroxy-3-methyl-1-naphthalenyl]oxy}-2-(trifluoromethyl)benzoate;
4-[(4-{[3-methyl-6-(metiloksi)-2-phenyl-1-naphthalenyl]oxy}phenyl)oxy]butane acid;
2-({2-[(4-{[3-methyl-6-(metiloksi)-2-phenyl-1-naphthalenyl]oxy}phenyl)oxy]ethyl}oxy)ethanol.
15. Pharmaceutical composition having the ability to bind ERα - and ERβ-estrogen receptors containing an effective amount of a compound according to claims 1 to 14 and a pharmaceutically acceptable Eitel.
16. The compound according to claims 1-14, with the ability to bind ERα - and ERβ-estrogen receptors.
17. The use of compounds according to claims 1 to 14 in the manufacture of medicaments for use in treating or preventing conditions or disorders associated with selective modulation of estrogen receptors.
18. The use of compounds according to any one of claims 1 to 14 in the manufacture of medicaments for use in treating or preventing osteoporosis, bone demineralization, reduced mass, density or growth of bone, osteoarthritis, obesity, cardiovascular disease or cardiac dysfunction, congestive heart failure, breast cancer, diabetes, depression, depressive symptoms, vaginal dryness, pruritus, dyspareunia, rheumatoid arthritis, menopausal or postmenopausal disorders, vasomotor symptoms, urogenital or valvano-vaginal atrophy, atrophic vaginitis, endometriosis, female sexual dysfunction, for enhancing libido, for the treatment of hypoactive sexual disorder, sexual arousal disorder, for increasing the frequency and intensity of orgasms.
19. Method bind ERα - and ERβ-estrogen receptors, which is administered an effective amount of a compound according to any one of claims 1 to 14.
|
Complexonate nitrylotri(methylenphosphonat)-2-phenyl-3-ethyl-8-oxychinolin sodium salts salt-deposition inhibitor / 2337915
Amorphous alendronate monosodium, methods of production, based pharmaceutical composition and method of inhibition of bone resobrtion / 2334751
Carboxylic acid derivative with condensed rings and pharmaceutical composition based on it / 2195448
